Solid Biosciences closed at $6.52 on Nov 4, up 3.82%, 41.5% below its 52-week closing high. Volume of 1.1M shares was 0.80× its 20-day average (close to normal).
Split-adjusted performance: -5.8% over one month, -9.4% over six months, +25.4% over one year.
Short interest was 12.3M shares at the Oct 15 settlement, down 3.3% from the prior report (17.8% of float, 8.5 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SLDBSolid Biosciences | $6.52 | +3.82% | −9.4% | — | — | — | $699.1M | |
| CADLCandel Therapeutics | $9.05 | +2.61% | +18.6% | — | — | — | $692.5M | Compare |
| AURAAura Biosciences | $6.65 | +6.57% | −19.8% | — | — | — | $689.6M | Compare |
| ATTOAttovia Therapeutics | $15.60 | +2.16% | — | — | — | — | $712.2M | Compare |
| FDMT4D Molecular Therapeutics | $12.28 | +2.76% | +17.9% | +25106.7% | −1929.0% | — | $678.4M | Compare |
| SANASana Biotechnology | $2.56 | +4.92% | −29.7% | — | — | — | $766.4M | Compare |
| DNAGinkgo Bioworks Holdings | $11.65 | +8.27% | +15.6% | −48.5% | −231.7% | — | $784.5M | Compare |
| CGEMCullinan Therapeutics | $12.49 | −20.70% | −16.7% | — | — | — | $803.8M | Compare |
| PRMEPrime Medicine | $4.97 | +9.23% | +45.7% | +3.5% | −3649.0% | — | $901.4M | Compare |
No recent articles focused on Solid Biosciences. 1 articles mention it in passing.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
